Cubist Pharmaceuticals, Inc announced that a trial date has been set for patent litigation in the US District Court for the District of Delaware against Teva Parenteral Medicines, Inc (TPM), Teva Pharmaceuticals USA, Inc and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist's US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016. The Court has set a date for trial beginning on April 25, 2011. The court also scheduled a claim construction hearing (a.k.a. Markman hearing) for June 2, 2010. The court indicated that summary judgement motions will not be permitted in this lawsuit.

Cubist filed the lawsuit in response to an Abbreviated New Drug Application (ANDA) filed by TPM seeking US Food and Drug Administration (FDA) approval to market a generic version of daptomycin prior to the expiration of Cubist's patent rights. Daptomycin is marketed in the US and internationally under the brand name Cubicin (daptomycin for injection) as therapy for serious skin and bloodstream infections caused by certain Gram-positive bacteria.

Cubist Pharma is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.